Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2002

View Archived Issues

Versicor and Pharmacia focus on improving activity and spectrum of oxazolidinones

EMEA recommends approval for desloratadine syrup and rapidly disintegrating tablets

Lexicon validates new drug target in depression

Sepracor and 3M join forces to manufacture Xopenex HFA metered-dose inhaler

Vertex moves new drug candidate VX-799 into development for sepsis

Successful completion of clinical trial of inhaled human growth hormone

Actimmune enters phase II trial for treatment of liver fibrosis

Pilot study evaluates Natrecor in chronic heart failure outpatients

Avaden hormone replacement therapy receives French approval

Prescient NeuroPharma licenses anhydrovinblastine to Access Oncology

Major European launch announced for Kaletra

Endothelial cell-specific inhibition of protein synthesis demonstrated for tumstatin

Antisense oligonucleotide targeting Ki-ras as an approach to colorectal cancer

Specific, small-molecule inhibitor of P-selectin with antiinflammatory properties

Cell adhesion inhibitor IS-741 effective in rat model of IBD

Potent and selective OX2 receptor antagonists identified by Banyu

Gastric and cholecystokinin receptor ligands claimed in patents by James Black researchers

New Kissei compounds have potential for lowering lipids and protecting the liver

HGS and CAT form TRAIL-R1 antibody partnership

5-HT7 receptor antagonists synthesized at BMS

Solvay presents piperazine and piperidine compounds and potential uses

CD40-targeted MAb moves to clinical development at Genentech

Alexion's 5G1.1 completes phase I pilot study

DGI BioTechnologies and Novo Nordisk enter collaboration for cancer agents

CSL obtains marketing and distribution license to Angiomax in Australia

Two phase II trials of Neotrofin initiated in chemotherapy-induced neuropathy

MC-1 receives FDA approval for entry into phase II

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
ATNM-400 radioconjugate shows efficacy in resistant breast cancer
BioWorld Science
Although hormone receptor-positive (HR+) breast cancer accounts for over 70% of cases, 20%-30% of patients still experience relapse despite endocrine therapies...